This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Myocardial infarction (MI), stroke, peripheralarterialdisease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
(Photo: Business Wire milla1cf Thu, 01/18/2024 - 14:05 January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for patients with below-knee peripheralarterialdisease (PAD) were performed successfully using its Finesse Injectable balloon catheter platform.
This unique case highlights the diagnostic and therapeutic challenges of a patient with multiple vascular risk factors who suffered from strokes secondary to BHS.MethodsA 79‐year‐old man with a past medical history of peripheralarterydisease, abdominal aortic aneurysm, myocardial infarction with drug eluding stents (on dual antiplatelet therapy (DAPT)), (..)
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheralarterydisease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with PeripheralArteryDisease (PAD).
10, 2025 A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio. Lorraine and Bill Dodero tim.hodson Fri, 02/14/2025 - 15:33 Feb.
Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and nonVeterans Affairs encounters.ResultsThe mean age was 70.6 were male, and 18.5%
10, 2025 A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio. Lorraine and Bill Dodero tim.hodson Fri, 02/14/2025 - 15:33 Feb.
Researchers analyzed more than 145 million records covering every adult patient admitted to hospital in England over a nine-year period to establish the risk of long-term health outcomes following a heart attack -- in the largest study of its kind.
Association between clusters and the composite of (i) heart failure hospitalization or all-cause death, (ii) cardiovascular (CV) hospitalization or all-cause death, and (iii) major adverse CV events was assessed. Clusters were identified using both clinical and biological variables.
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary arterydisease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
years of age, P <0.001), cerebral or peripheralarterydisease (6.2% There may be no better study to symbolize the dysfunction that has invaded cardiology than the VIRGO trial, a study examining the outcomes of young patients (18-55) presenting to the hospital with a heart attack. years of age versus 59.0±8.4
Objective Historical reductions in cardiovascular disease (CVD) due to lifestyle and treatment improvements are now threatened by factors such as increasing obesity and diabetes, but the relative importance of different risk factors varies by CVD condition.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content